GeneTex, Inc.
6.6.2023 15:05:40 CEST | ACCESS Newswire | Press release
IRVINE, CA / ACCESSWIRE / June 6, 2023 / GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform to produce best-in-class biomedical research reagents. The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies. GeneTex has employed this process to develop and thoroughly validate its new programmed death-ligand 1 (PD-L1) recombinant rabbit monoclonal antibody for immunohistochemistry (IHC).
The interaction between PD-L1 (CD274/B7-H1) and its receptor programmed death-1 (PD-1) is not only a focus of cancer immunotherapy research but also has major therapeutic relevance for many solid malignancies. PD-L1 is an immune checkpoint inhibitor that binds to PD-1 expressed on T cells and other effectors to quash immune system overactivation and autoimmunity. Cancer cells exploit this and overexpress PD-L1, creating an immunosuppressive state through induced cell death of anti-tumor T cells. Thus, gauging PD-L1 expression on tumor cells can identify cancers that may respond to anti-PD-L1/PD-1 agents. Given the importance of PD-L1 detection in patient tumor samples for both prognostic and treatment considerations, reliable reagents are clearly essential for both research and clinical decision-making.
Immunohistochemistry is utilized routinely in both academic and clinical settings to determine PD-L1 expression in both normal and cancerous tissues. GeneTex's recombinant rabbit monoclonal antibody (PD-L1 antibody [HL1041]) is a cited, PD-L1-specific, knockout-validated reagent that performs in three applications (i.e., western blot, immunocytochemistry, and IHC). To further evaluate this antibody's IHC capabilities, GeneTex enlisted the assistance of MS Validated Antibodies GmbH (MSVA), a company with demonstrated proficiency in IHC optimization that has assessed over 5000 antibodies for their functionality in formalin-fixed tissue IHC. MSVA completed an extensive analysis of the GeneTex antibody's staining on tumor samples and a broad array of normal tissues, comparing the signal to that of another well-established PD-L1 antibody (see Figure). GeneTex clone [HL1041] exhibited excellent sensitivity and specificity. Marco Sauter, MSVA CEO, commented, "As formalin fixation alters the structure and accessibility of many epitopes, a trustworthy antibody validation for IHC invariably requires the analysis of a very broad range of formalin-fixed tissues. Our analysis of more than 70 different normal tissue types and of a broad range of different cancers exceeds what regulatory agencies currently require. We are gratified that our MSVA approach could help to identify PD-L1 clone [HL1041] with binding properties that are comparable to the most established PD-L1 antibodies on the market."
The need for quality antibodies to visualize the expression of biomarkers crucial for cancer biology research and patient care remains vast, particularly for IHC. GeneTex is presently developing reagents against a number of key targets. Allen Lee, GeneTex's Vice President of Business Development, stressed the importance of expertise-based collaborations to create gold-standard products for scientists and clinicians: "GeneTex is excited to extend our partnership with MSVA. Their IHC validation services align perfectly with GeneTex's core mission, which is to provide the biomedical community with the highest quality immunological reagents supported by extensive research, development, and validation."
GeneTex products are for research use only. Not for diagnostic or therapeutic procedures.
Media Contact:
Allen Lee
Phone: 949.553.1900
Email: allensl@genetex.com
www.genetex.com
Contact Information
Allen Lee
Vice President - Business Development
allensl@genetex.com
(949)553-1900
SOURCE: GeneTex, Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/759287/GeneTex-Launches-PD-L1-Antibody-Comprehensively-Validated-by-MS-Validated-Antibodies-GmbH-for-Immunohistochemistry
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Leggett Dynamics Launches Mid-Class Massage System & Makes Luxury Comfort Accessible on High-Volume Programs22.6.2026 13:00:00 CEST | Press release
DETROIT, MI / ACCESS Newswire / June 22, 2026 / Leggett Dynamics today launched its Mid-Class Massage System (MCM), a breakthrough non-electronic innovation that makes premium massage more accessible beyond the luxury vehicle segment. Now in production with a global OEM, MCM was also shortlisted for the 2026 Auto Tech Partnership Award for industry-leading innovation and collaboration. Breakthrough by Design MCM creates a distinctive massage experience with a compact 30 x 35 mm module that uses the Coandă effect, an air jet's natural tendency to follow a curved surface. With no electronics or moving parts, it reduces complexity and cost, making a premium experience accessible to more vehicle segments and consumers. Balancing Innovation, Speed and Cost "Automakers must balance innovation, speed and cost while consumers expect more personalized, affordable, premium experiences," said Julien Rea, VP of Global Innovation & Engineering at Leggett Dynamics. "Leggett Dynamics' Mid-Class Massa
EcoModular Advances EIC STEP Scale Up Application to Support European Manufacturing Expansion22.6.2026 09:55:00 CEST | Press release
AI-native robotics platform engages European innovation-funding specialist Catalyze to prepare its submission to the European Innovation Council's STEP Scale-Up programme, with its EU Manufacturing Hub as the anchor of a planned European scale-up DUBLIN, IE / ACCESS Newswire / June 22, 2026 / EcoModular, the AI-native robotics platform for volumetric manufacturing operated by Ascotway Limited and advancing a Nasdaq Capital Market direct listing, today announced that it has engaged Catalyze B.V., a leading European innovation-funding consultancy, to prepare and submit an application to the European Innovation Council (EIC) STEP Scale-Up programme. The application is being prepared for the programme's evaluation batch dated 9 September 2026. The EIC STEP Scale-Up programme forms part of the European Union's Strategic Technologies for Europe Platform (STEP) and is administered by the European Innovation Council. It is designed to provide investment support to European companies scaling st
Bear Robotics to Acquire Kinisi Robotics, Completing Its End-to-End Physical AI Robotics Platform22.6.2026 09:00:00 CEST | Press release
Kinisi adds the manipulation AI layer that completes Bear's multi-robot Physical AI platform - extending Bear's deployed fleet from moving and delivering to handling physical work itself. REDWOOD CITY, CA / ACCESS Newswire / June 22, 2026 / Bear Robotics today announced it has signed a definitive agreement to acquire Kinisi Robotics, in a transaction that will make Kinisi part of Bear. On closing, Kinisi's KR1 humanoid robot, its Bristol-based engineering team, and its Physical AI capabilities will be integrated into Bear Robotics, completing Bear's end-to-end Physical AI robotics platform. The transaction is expected to close in the coming days. Bear has built the world's most widely deployed fleet of service robots - more than 16,000 shipped into commercial service worldwide. Bear's robots already work together as one coordinated team through agentic multi-robot orchestration, moving freely through busy, changing spaces instead of following fixed tracks or routes. Most robotics compa
Ore Energy and Budget Thuis to Deploy 1 GWh of Multi-Day Iron-Air Energy Storage in a First for European Energy Suppliers22.6.2026 09:00:00 CEST | Press release
Dutch energy supplier commits to 1 GWh of iron-air energy storage to reduce consumer energy costs; First 400 MWh to be delivered in 2028 AMSTERDAM, NL / ACCESS Newswire / June 22, 2026 / Ore Energy, the Netherlands-based iron-air multi-day energy storage company, today announced an agreement with Budget Thuis, one of the largest Dutch energy suppliers, to deploy 1 GWh of iron-air long-duration energy storage (LDES). The agreement represents the largest iron-air energy storage offtake in continental Europe to date and the first with a European energy supplier. The agreement begins with a committed 400 MWh first phase planned for delivery in 2028. For Budget Thuis, the agreement is a strategic move to provide customers with more stable, affordable, and increasingly clean electricity as the Dutch power system becomes more dependent on wind energy. Ore Energy's multi-day storage technology is designed to store renewable electricity when it is abundant and dispatch it across extended low-re
Driving the World's Leading Supply Chains: 9 OMP Customers Named to The 2026 Gartner Top 2518.6.2026 15:00:00 CEST | Press release
As global leaders move from firefighting to foresight, OMP celebrates the enterprise visionaries scaling decision-driven intelligence at the speed of change. ANTWERPEN, BE / ACCESS Newswire / June 18, 2026 / OMP, a leading AI-powered provider of supply chain planning solutions, extends its congratulations to the 9 customer organizations recognized in the newly released Gartner® Supply Chain Top 25 and Masters for 2026. Now in its 22nd year, the Gartner Supply Chain Top 25 remains the definitive benchmark for supply chain excellence, evaluating global enterprises on financial performance, ESG initiatives, and community opinion. This year's rankings point to three capabilities separating market leaders: building an autonomous workforce where people and intelligent systems collaborate on decisions, adopting network-centric strategies that treat supply chain design as a continuous, adaptive process, and orchestrating decisions end-to-end across increasingly complex ecosystems. OMP's custom
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom